Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the children's cancer group

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3037-3043

  Nicholson, H Stacy ^a   Krailo, Mark ^b   Ames, Matthew M ^b   Seibel, Nita L ^b   Reid, Joel M ^b   Liu Mares, Wen ^b   Vezina, L Gilbert ^b   Ettinger, Alice G ^b   Reaman, Gregory H ^b  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0031686970     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3037     Document Type: Article

References (20)

1. Newlands ES, Stevens MFG, Wedge SR, et al: Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61, 1997
2. Heriat P, Rougier P, Oliveira J, et al: Phase II study of mitozolomide (M&B 39565) in colorectal and breast cancer. Invest New Drugs 6:323-325, 1988
3. Blackledge G, Roberts JT, Kaye SB, et al: Phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 25:391-392, 1989
4. Harding M, Northcott D, Smyth J, et al: Phase II evaluation of mitozolomide in ovarian cancer. Br J Cancer 57:113-114, 1988
5. Neijt JP, van der Burg ME, Guastalla JP, et al: Phase II trial of mitozolomide in patients with advanced ovarian cancer: A study of the EORTC Gynecological Cancer Cooperative Group. Acta Oncol 28:663-665, 1989
6. Van Oosterom AT, Stoter G, Bono AV, et al: Mitozolomide in advanced renal cancer: A phase II study in previously untreated patients from the EORTC Genitourinary Tract Cancer Cooperative Group. Eur J Cancer Clin Oncol 25:1249-1250, 1989
7. Gundersen S, Aamdal S, Fodstad L: Mitozolomide (NSC 35451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease. Br J Cancer 55:433-435, 1987
8. Schornagel JH, Simonetti G, McVie JG: Phase I study of mitozolomide (NSC 54351) using a daily X 5 schedule. Proc Fifth National Cancer Institute-European Organization for Research and Treatment of Cancer Symposium on New Drugs in Cancer Therapy. Amsterdam, the Netherlands, October 22-24, 1986 (abstr)
9. Stevens MFG, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5862, 1987
10. Newlands ES, Blackledge GRP, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992
11. Bleenen NM, Newlands ES, Lee SM, et al: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913, 1995
12. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 29A:940-942, 1993
13. Newlands ES, O'Reilly SM, Glaser MG, et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32:2236-2241, 1996
14. Woll PJ, Crowther D, Johnson PW, et al: Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 72:183-184, 1995
15. Ries LAG, Miller BA, Handey BF, et al (eds): SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Bethesda, MD, National Cancer Institute. National Institutes of Health publication no. 94-2789, 1994
16. Pollack IF: Brain tumors in children. N Engl J Med 331:1500-1507, 1994
17. Plowman J, Waud WR, Koutsoukos AD, et al: Pre-clinical antitumor activity of temozolomide in mice; Efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54:3793-3799, 1994
18. Friedman HS, Dolan ME, Pegg AE, et al: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55:2853-2857, 1995
19. 6-alkylguanine DNA alkyltransferase with twice-daily oral temozolomide (SCH 52365) in patients with advanced cancer. Proc Am Soc Clin Oncol 15:178, 1996 (abstr 366)
20. Newlands ES, Rustin GJS, Evans H, et al: Phase I trial of oral temozolomide administered over 6 and 7 weeks. Proc Ninth National Cancer Institute-European Organization for Research and Treatment of Cancer Symposium on New Drugs in Cancer Therapy 345. Amsterdam, the Netherlands, March 12-15, 1996 (abstr)